title: Promising Novel Agents for Aggressive B-Cell Lymphoma.
abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in the western world. Current treatment regimens result in curing approximately 50% to 60% of patients with DLBCL. In 2006, the Food and Drug Administration approved rituximab for use in the first-line treatment of patients with DLBCL in combination with anthracycline-based chemotherapy regimens. Since then, no other agents have been approved for the treatment of DLBCL. This article reviews recent data on the most promising agents in development for the treatment of DLBCL.
authors.affiliation: Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Electronic address: younesa@mskcc.org.
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
mesh_terms: D018943:Anthracyclines / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis; D000069283:Rituximab / Q000627:therapeutic use
chemical_list: D018943:Anthracyclines; D000069283:Rituximab
keywords: B-cell receptor; BCL2 inhibitor; Diffuse large B-cell lymphoma; EZH2 inhibitor